Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (40): 7501-7504.doi: 10.3969/j.issn.1673-8225.2011.40.021

Previous Articles     Next Articles

Intravenous application of busulfan in the conditioning regimen of hematopoietic stem cell transplantation

Yao Zhi-juan, Meng Qing-xiang, Zhang Hong-yu, Wang Jun, Zhang Wen-li, Wen Juan-juan, Guo Nai-lan   

  1. Department of Hematology, Shenzhen Hospital, Peking University, Shenzhen  518036, Guangdong Province, China
  • Received:2011-04-03 Revised:2011-08-10 Online:2011-10-01 Published:2011-10-01
  • Contact: Meng Qing-xiang, Master, Chief physician, Department of Hematology, Shenzhen Hospital, Peking University, Shenzhen 518036, Guangdong Province, China Mengqxbdsy@126.com
  • About author:Yao Zhi-juan★, Master, Associate chief physician, Department of Hematology, Shenzhen Hospital, Peking University, Shenzhen 518036, Guangdong Province, China ddz1988@gmail.com
  • Supported by:

    the grant from Shenzhen Science and Technology Bureau, No. 200803031*

PDF

329

Abstract:

BACKGROUND: Busulfan is commonly used in bone marrow or peripheral blood stem cell transplantation pretreatment, which is mainly metabolized in the liver.
OBJECTIVE: To evaluate the efficacy and safety of the conditioning regimen using intravenous busulfan in hematopoietic stem cell transplantation for malignant hematopathy.
METHODS: A total of 43 patients receiving intravenous busulfan as conditioning regimen were included to observe regimen-related toxicity (hepatotoxicity, neurotoxicity, mucositis), engraftment time, acute graft-versus-host disease (aGVHD), overall survival, and leukemia relapse.
RESULTS AND CONCLUSION: Thirty-one patients (72%) had a rise in the level of alanine aminotransferase. Untypical hepatic veno-occlusive syndrome occurred in 2 patients (5%). One patient had numbness on a couple of hands. Twenty-six patients (60%) had mucositis. The engraftment time of neutrophil was 16 days and that of platelet was 12 days. Delayed platelet engraftment was in 2 cases of autologous hematopoietic stem cell transplantation. The occurrence of aGVHD Ⅰ-Ⅱ was 63% (24/38). The overall survival was 72% (31/43). The relapsed rate was 23% (10/43). The conditioning regimen with intravenous busulfan in hematopoietic stem cell transplantation was effective and safe, and patients had better tolerance.

CLC Number: